Ivonn Mosquera
Nurse Practitioner · Boca Raton, FLNPI 1689224446
Payments from drug & device makers
Across 334 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$843
- Amneal Pharmaceuticals LLC$760
- Otsuka America Pharmaceutical, Inc.$722
- Lilly USA, LLC$714
- EMD Serono, Inc.$594
- Teva Pharmaceuticals USA, Inc.$534
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$7,81199%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 64 | $843 |
| Amneal Pharmaceuticals LLC | 61 | $760 |
| Otsuka America Pharmaceutical, Inc. | 24 | $722 |
| Lilly USA, LLC | 24 | $714 |
| EMD Serono, Inc. | 11 | $594 |
| Teva Pharmaceuticals USA, Inc. | 14 | $534 |
| AbbVie | 20 | $507 |
| Neurelis, Inc. | 10 | $360 |
| MDD US Operations, LLC | 16 | $358 |
| AstraZeneca | 16 | $309 |
| Johnson & Johnson | 2 | $254 |
| Lundbeck LLC | 9 | $220 |
| Novocure Inc. | 2 | $208 |
| Merz Pharmaceuticals, LLC | 9 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $171 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Acorda Therapeutics, Inc | 5 | $119 |
| Bristol Myers Squibb | 1 | $117 |
| Kyowa Kirin, Inc. | 5 | $105 |
| Eisai Inc. | 3 | $83 |
| CSL Behring | 4 | $79 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Almatica Pharma LLC | 3 | $55 |
| UCB, Inc. | 2 | $47 |
| Greenwich Biosciences, Inc. | 2 | $41 |
| Corium, LLC | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Sanofi | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Nalu Medical, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Viz.ai, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Aprecia Pharmaceuticals, LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Springworks Therapeutics, Inc. | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
| Curonix LLC | 1 | $13 |
| Grifols USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,857 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 48 | $247,976 |
| InbrijaLevodopa | 11 | $54,809 |
| RytaryCarbidopa/Levodopa | 61 | $53,831 |
| RexultiBrexpiprazole | 25 | $35,689 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,580 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,854 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 186 | $5,339 |
| Memantine Hcl | 119 | $2,652 |
| Gabapentin | 150 | $2,622 |
| Galantamine ErGalantamine Hbr | 31 | $2,433 |
| Midodrine Hcl | 18 | $1,742 |
| Galantamine Hbr | 20 | $1,503 |
| Donepezil Hcl | 177 | $1,282 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 31 | $1,166 |
| Primidone | 41 | $1,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $843 | $247,97648 claims |
| Acorda Therapeutics, IncInbrija | $119 | $54,80911 claims |
| Amneal Pharmaceuticals LLCRytary | $760 | $53,83161 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $722 | $35,68925 claims |
| PfizerNurtec Odt | $15 | $14,85414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Boca Raton
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.